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ABSTRACT
Antibiotic resistance is a major public health challenge worldwide, whose implications for global health might be
devastating if novel antibacterial strategies are not quickly developed. As natural predators of bacteria, (bacterio)phages
may play an essential role in escaping such a dreadful future. The rising problem of antibiotic resistance has revived the
interest in phage therapy and important developments have been achieved over the last years. But where do we stand
today and what can we expect from phage therapy in the future? This is the question we set to answer in this review. Here,
we scour the outcomes of human phage therapy clinical trials and case reports, and address the major barriers that stand
in the way of using phages in clinical settings. We particularly address the potential of phage resistance to hinder phage
therapy and discuss future avenues to explore the full capacity of phage therapy.
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INTRODUCTION
The discovery of antibiotics in 1928 and their introduction in
clinical practice has revolutionized the field of medicine. Since
then and for decades, antibiotics were used to treat a wide range
of severe infections, saving millions of lives (Davies and Davies
2010). However, nobody predicted what was about to come a
few decades later. As a consequence of antibiotic overuse and
misuse, bacteria managed to develop multiple antibiotic resis-
tance mechanisms, and the golden age of antibiotics has come
to an end (Davies and Davies 2010; Malik and Bhattacharyya
2019). We are currently facing a post-antibiotic era, in which
common infections or minor injuries can become fatal (WHO
2014). Recent reports state that more than 2.8 million antibiotic-
resistant infections occur each year in the United States and
that more than 35 000 people die as a result (Centers for Disease
Control 2019). In Europe, approximately 33 000 people die every
year from antibiotic-resistant infections (Cassini et al. 2019). If
no action is taken, the World Health Organization estimates that
drug-resistant infections could kill about 10 million people per
year by 2050. The search and development of new and effec-
tive antibacterial compounds is urgently required to avoid such
a threatening future, and (bacterio)phages might play a major
role in tackling this global crisis.
Phages are bacterial viruses and the most abundant enti-
ties on Earth (Clokie et al. 2011; Fernández et al. 2019). While
the use of phages in human therapy begun soon after their dis-
covery by Frederick Twort and Félix d’Hérelle over a century
ago, their application in clinical practice in Western countries
was quickly overshadowed by the introduction of antibiotics
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(Chanishvili 2012; Gordillo Altamirano and Barr 2019). In places
such as Georgia and Poland, phage therapy remained active until
today, mostly via two major phage therapy centres: the Eliava
Institute of Bacteriophages, Microbiology and Virology (Tblilisi,
Georgia) and the Ludwik Hirszfeld Institute of Immunology and
Experimental Therapy (Wroclaw, Poland) (Rohde, Wittmann and
Kutter 2018). Many patients with antibiotic-resistant infections
are traveling from multiple places in the world to these cen-
tres to receive individualized phage treatments as a last hope
(Rohde, Wittmann and Kutter 2018). Despite all the success cases
of patients treated with phages documented to date, the intro-
duction of phage therapy in Western countries still faces major
obstacles, especially regulatory issues (Fauconnier 2019). Now,
efforts to make phage therapy widely available are ongoing and
a number of clinical trials are being conducted in Europe and in
the United States (Sybesma et al. 2018; Fauconnier 2019). In this
review, we will first discuss the current state of phage therapy in
the Western world and then address the major challenges faced
by phage therapy and the future opportunities in this field.
THE CURRENT STATUS OF PHAGE THERAPY
The clinical use of phages to treat a wide range of infections
begun in the early 1920s. However, inconsistent results reported
about phage trials during the 1930s as well as the lack of con-
trols and inappropriate characterization, production and purifi-
cation of phage preparations raised important concerns about
the safety and efficacy of this therapy (Gordillo Altamirano and
Barr 2019). As such, phage therapy remained active only in a few
countries of Eastern Europe, where studies have provided sub-
stantial evidence of the efficacy of phages to treat certain infec-
tions with no adverse effects reported (Sulakvelidze, Alavidze
and Morris 2001; McCallin and Brüssow 2017). Still, the lack of
confirmation in line with evidence-based medicine, i.e. clinical
trials, fuels the reluctance of regulatory agencies and clinicians
from Western countries on the use of phage therapy (Sybesma
et al. 2018). To establish phage therapy as a feasible alternative to
antibiotics, clear efficacy data from randomized controlled clin-
ical trials is required (McCallin et al. 2019). To tackle this situa-
tion, an increasing number of clinical trials have been carried
out over the last years but only a few are currently completed
(Furfaro, Payne and Chang 2018; Rohde, Wittmann and Kutter
2018; Sybesma et al. 2018).
In 2009, Wright et al. reported a randomized, double-blind,
placebo-controlled phase I/II clinical trial approved by both UK
Medicines and Healthcare products Regulatory Agency (MHRA)
and the Central Office for Research Ethics Committees (COREC)
(Wright et al. 2009). This trial was carried out on 24 patients with
chronic otitis to assess the efficacy and safety of a phage prepa-
ration composed of six phages for the treatment of otitis caused
by antibiotic-resistant Pseudomonas aeruginosa. By the end of
the trial (day 42), all the clinical indicators (e.g. inflammation,
ulceration, discharge type and quantity, and odour) improved in
patients treated with phages, but only three of the 12 patients
receiving phage treatment were apparently cured. Importantly,
no serious adverse effects were reported (Wright et al. 2009). Also
in 2009, Rhoads and colleagues reported another randomized,
double-blind controlled study that addressed the safety (and
not efficacy) of a phage cocktail targeting P. aeruginosa, Staphylo-
coccus aureus and Escherichia coli for the treatment of venous leg
ulcers (VLU) (Rhoads et al. 2009). This first phage therapy trial in
the United States involved 42 patients with VLU. Patients were
topically treated with either phage cocktail or saline solution
(control) for 12 weeks with a follow-up period of up to 24 weeks.
No adverse effects were associated with phage treatment, but
no significant differences were found on the rate and frequency
of healing between phage-treated and control groups. This is not
surprising as the phages were not tested for infectivity on the
bacteria causing the VLU. According to the authors, the efficacy
of the phage preparation should be evaluated in a phase II effi-
cacy trial with a larger sample and with wounds infected with
bacteria susceptible to the phage cocktail (Rhoads et al. 2009).
The largest clinical trial on phage therapy conducted in
Europe and performed under both good manufacturing practices
(GMP) and good clinical practices (GCP) was the PhagoBurn trial,
launched in 2013. In this multicentre randomized controlled
phase I/II clinical trial, 27 patients suffering from burn wound
infections were recruited from hospitals located in France and
Belgium to be randomly treated with phage therapy (a cock-
tail of 12 lytic phages) or standard care (1% sulfadiazine sil-
ver emulsion cream) to compare the efficacy and tolerability of
both treatments in patients with wounds infected by P. aerugi-
nosa (Jault et al. 2019). Both treatments were topically adminis-
tered for seven days with a 14 days follow-up period. Overall,
the phage cocktail was able to decrease bacterial burden in burn
wounds but the progress was slower than in the control group
(standard treatment). On the positive side, no adverse effects
were found in the phage-treated group. The limited efficacy of
the phage cocktail was reported to be caused by a significantly
drop of the phage titre after GMP manufacturing, leading the
participants to receive a much lower concentration of phages
than initially estimated. More importantly, the susceptibility of
wound bacteria to the phage cocktail was not assessed prior to
treatment. In those patients in which phage treatment failed,
bacteria were later found to be resistant to low phage doses (Jault
et al. 2019).
Nestlé (Switzerland) also performed a phase I/II trial in col-
laboration with the Dhaka Hospital of the International Centre
for Diarrheal Disease Research, Bangladesh (Sarker et al. 2016).
This randomized double-blind, placebo-controlled trial was con-
ducted between 2009 and 2011 to assess the safety and efficacy
of oral administration of a T4-like phage cocktail or a placebo,
in children hospitalized with acute bacterial diarrhea. Although
the oral coliphages could reach the intestine, no phage replica-
tion was observed, and the treatment had no beneficial effects.
At the time, the authors attributed the failure to improve diar-
rheal outcome to the low host range coverage of the phage cock-
tail (i.e. some strains were not infected) and also the need of
higher oral phage doses (Sarker et al. 2016). Indeed, oral applica-
tion of phages without any protection (e.g. encapsulation of the
phages or neutralization of the stomach acid) prior to admin-
istration reduces the phage numbers reaching the intestine to
levels that might be insufficient for a visible therapeutic effect.
Later, it was also found that E. coli was not the main cause of
acute bacterial diarrhea, and therefore even an efficient phage
treatment of E. coli would not result in improved diarrheal out-
come (Satter et al. 2017; Nelson et al. 2018). This Nestlé trial and
the clinical trial developed by Rhoads et al. highlight the impor-
tance of identifying the etiologic agent(s) causing infection and
of checking for phage susceptibility prior to treatment. There-
fore, phage therapy clinical trials must be carefully designed
to avoid potential problems that might impair the outcome of
the treatment. Recently, Ooi et al. reported a clinical trial aim-
ing to assess the safety, tolerability and preliminary efficacy
of a phage cocktail composed of three lytic phages, applied
intranasally in patients with recalcitrant chronic rhinosinusitis
(CRS) caused by S. aureus (Ooi et al. 2019). In this open label, phase
I clinical trial, only patients carrying a clinical isolate sensitive
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to the phage cocktail were considered. Overall, the twice-daily
intranasal irrigation of phages was safe and well tolerated by
the nine patients through the 14 days treatment, with no serious
adverse events reported. While the preliminary efficacy observa-
tions seem promising (two of the nine patients had eradication
of infection), the authors highlighted the need for a randomized
clinical trial to determine the optimal dose regimen and demon-
strate the efficacy of the phage cocktail (Ooi et al. 2019). The high
safety of phage therapy has already been reported in multiple
patients from the phage therapy unit in Poland (Międzybrodzki
et al. 2012; Rogóż et al. 2019).
While most clinical trials have failed to provide unequivo-
cal evidence of the efficacy of phage therapy, the number of
case studies in which phage therapy was successfully used to
treat life-threatening infections is increasing (Table 1) (Sybesma
et al. 2018; McCallin et al. 2019). Some of these successful cases
have reached the media (Dedrick et al. 2019; Strathdee, Patterson
and Barker 2019), fostering the interest of the global commu-
nity in this therapy. One of these newsworthy cases concerned
a 68-year-old man who suffered from necrotizing pancreatitis
complicated by an Acinetobacter baumannii multidrug-resistant
infection (Schooley et al. 2017). Despite multiple rounds of antibi-
otic treatments, the patient condition rapidly deteriorated over
time. Therefore, the A. baumannii strain isolated from the patient
was used to screen for phages in two different laboratories,
which made possible to compose phage cocktails tailored for
the patient. Phage administration (via catheters into the abdom-
inal cavity and also intravenously) rapidly reverted the clinical
condition of the patient by clearing the infection (Schooley et al.
2017). Phage therapy documentaries have also been broadcasted
on television in many countries (Djebara et al. 2019). As a con-
sequence, the Queen Astrid military hospital in Brussels, Bel-
gium, has experienced a huge increase in external phage ther-
apy requests since 2017 (Djebara et al. 2019). The majority of
these requests were initiated by the patients themselves and
came mostly from the Netherlands followed by Belgium and
France. Among the 260 phage therapy requests received by the
hospital between 2013 and 2018, only 15 patients, who were
infected with bacterial pathogens susceptible to the available
phages, received treatment but these data were not yet reported
(Djebara et al. 2019).
The rising interest in phage therapy by patients and physi-
cians and the consequent increase of requests for phages from
all over the world highlights a growing need for the establish-
ment of phage banks with well characterized phages that could
facilitate access by the international community. Some phage
banks have already been established, such as the Félix d’Hérelle
Reference Center for Bacterial Viruses at the University of Laval
(Québec, Canada), the Leibniz Institute DSMZ German Collec-
tion of Microorganisms and Cell Cultures (Braunschweig, Ger-
many), the Bacteriophage Bank of Korea (Yongin, South Korea),
the American Type Culture Collection (ATCC) Bacteriophage Col-
lection (Virginia, USA), the National Collection of Types Cultures
(NCTC) Bacteriophage Collection (Salisbury, UK) (McCallin et al.
2019; Sacher 2019), and the Fagenbank (Delft, the Netherlands).
It is important that phage researchers feed these global phage
banks to have a larger coverage of (pathogenic) bacterial species.
CURRENT CHALLENGES IN PHAGE THERAPY
Quality and safety requirements
The success of phage therapy is highly dependent on the
safety of phage preparations, which raises manufacturing and
formulation challenges (Fig. 1A). For broad medical applications,
phages would need to be produced in large scale under Good
Manufacturing Practices (GMP) approved by regulatory agencies
(Regulski, Champion-Arnaud and Gabard 2018). Although
the production of phages for therapy must comply with the
strict regulations that are usually applied for pharmaceutical
products to ensure the high quality standards appropriate for
their intended use, no clear guidelines were yet developed
specifically for phage manufacturing (Mutti and Corsini 2019).
To address this issue, a group of phage researchers have set
some quality and safety requirements for sustainable phage
therapy products (Pirnay et al. 2015). One of the requirements
is to avoid phages encoding for lysogeny, virulence factors or
antibiotic resistance. However, this might limit the use of phage
therapy in some fastidious bacteria for which no strictly viru-
lent phages have been found so far, such as Clostridium difficile
(Hargreaves and Clokie 2014).The presence of impurities such
as endotoxins in phage preparations should also be avoided
or be below a threshold (Pirnay et al. 2015). Several purification
methods have been developed and optimized to remove these
toxic elements from phage preparations (Hietala et al. 2019), but
none has reached optimal results so far.
It is important to note that as phages are biological entities,
the development of robust manufacturing processes in compli-
ance with GMP is also essential to avoid variability among phage
preparations (Garcı́a et al. 2019; Mutti and Corsini 2019). Another
important aspect is the quality control of phage stock prepara-
tions. This should be regularly assessed by checking for their sta-
bility (shelf life), sterility and cytotoxicity, as well as by perform-
ing periodic pH measurements (Merabishvili et al. 2009; Pirnay
et al. 2015). Although recent progress in phage manufacturing
has revitalized phage therapy in Western countries, there is still
a long way to go before a general approval is reached for the
use of phage therapy (Regulski, Champion-Arnaud and Gabard
2018).
Stability of phage preparations
The stability of phage preparations is a key requirement for suc-
cessful treatment and also for the regulation of phages as phar-
maceuticals. A potential phage candidate for therapy should
have a good shelf life, i.e. it should be stored in a formulation
that ensures activity without significant drop in phage titre dur-
ing processing and long-term storage (Fig. 1B), as such decrease
might compromise the outcome of the treatment (Malik et al.
2017; Merabishvili, Pirnay and De Vos 2018; Jault et al. 2019). Sev-
eral strategies have been developed and optimized to improve
phage stability and the most common include spray-drying,
freeze drying, extrusion dripping methods, emulsion and poly-
merisation techniques (Malik et al. 2017). However, phage sta-
bility in different formulations (e.g. liquids, gels, powders) is
highly variable, especially among different phage types (Leung
et al. 2017; Gonzalez-Menendez et al. 2018; Merabishvili, Pirnay
and De Vos 2018). An alternative strategy to improve the storage
shelf life of phages is their encapsulation on different matrices
such as liposomes, alginate, cellulose or other polymers (Malik
et al. 2017; Cortés et al. 2018). Phage encapsulation strategies are
important not only to achieve longer shelf life but also for thera-
peutic purposes. Because treatment efficacy highly depends on
phage concentration at the site of infection, protecting phages
from the harsh conditions found in the human body is vital
to avoid phage inactivation during treatment due to e.g. low
pH or clearance mechanisms associated with the immune sys-
tem (Malik et al. 2017; Dąbrowska 2019). In fact, the immune
system plays a crucial role in phage clearance or inactivation
from animal and human bodies. Most studies on the immune
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Figure 1. Current challenges and emerging approaches in phage therapy. Phage therapy currently faces challenges such as (A), conforming to the current quality
and safety requirements, (B), guaranteeing stability of phage preparations for long periods of time, (C), developing a high-throughput assay for phage screening,
(D), overcoming the limited activity of phages in biofilms, (E), controlling and overcoming the development of bacterial resistance to phages and (F), establishing a
regulatory framework more adequate to phage products. Simultaneously, different approaches are being developed to improve phage therapy, which include (G), the
use of combined approaches such as the use of both phages and antibiotics or (H), the exploitation of synthetic biology tools to engineer phages with improved features.
This figure was created with BioRender.com and exported under a paid subscription.
response to phages have focused on the development of phage-
specific antibodies (adaptive immunity). These have been shown
in many cases to decrease the circulation of phages, but other
studies have reported no antibody formation or no effect of the
formed antibodies on the ability of phages to clear the infection
(Dąbrowska 2019). In vitro and in vivo studies have demonstrated
the ability of encapsulated phages to persist for longer periods at
low pH, enhancing the efficacy of oral administration in animal
models (Yongsheng et al. 2008; Ma et al. 2012; Colom et al. 2017;
Otero et al. 2019; Vinner et al. 2019). More studies are required to
understand protection given by encapsulated strategies against
immune clearance of phages. The protection of phages is also
important for certain combined therapies that can inactivate
phages when applied together and impair the outcome of the
treatment. As an example, burn wound care products and their
active ingredients usually exhibit high acidity that can neg-
atively affect the activity of phages in wounds (Merabishvili
et al. 2017).
Another issue of phage stability is the occurrence of spon-
taneous mutations in phage stocks stored for long periods
or accumulated during phage production and manufacturing,
which can impair viral fitness (Drake 1966; Botka et al. 2019).
Although difficult, it would be helpful to predict phage evolu-
tion during production to set up a manufacturing process that
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would minimize the mutation rates in phage genomes (Garcı́a
et al. 2019).
Fast phage screening methods
Due to the high specificity of phage activity, finding a phage
that targets a particular strain often requires the screening of
large phage collections (Fig. 1C). The most traditional method
to detect phage activity against a strain is the double layer agar
(DLA) method, in which different phages are spotted on top of a
lawn of the bacteria of interest (Cornax et al. 1990; Kropinski et al.
2009). Depending on the growth rate of the particular strain to
target, results may take up to 48 h to show and therefore the DLA
method is not convenient in a therapeutic context where fast
diagnosis is crucial. High-throughput and fast-screening meth-
ods are desirable to rapidly identify phage(s) able to efficiently
infect the target strain(s).
Multiple methods have been developed for the detection and
quantification of phages, via direct or indirect measurements,
but few seem to have application in a clinical setting. For exam-
ple, real-time PCR (qPCR) methodologies (Del Rio et al. 2008;
Ly-Chatain et al. 2011) have been developed for fast and sen-
sitive detection of phages and for the identification of infec-
tion via detection of increasing phage concentrations. But qPCR
methods require a set of primers and optimized conditions for
(almost) every phage, which is neither high-throughput nor fea-
sible when testing large (and fast expanding) phage collections
against a target strain.
Flow cytometry has also been used to reveal phage infec-
tion via detection of cells with low-density cell walls (Michelsen
et al. 2007). Low-density cell walls have been observed as a con-
sequence of phage infection in Lactococcus lactis. The method
allows for fast and early detection of phage infection, but is
low-throughput and most likely not universal for all bacterial
species and/or phages. Some other works have detected phage
propagation indirectly via measuring enzyme release from bac-
terial cells due to phage-induced cell lysis. Intracellular enzymes
such as adenylate kinase and adenosine 5’-triphosphate (ATP)
or β-galactosidase have been tested as measurements of infec-
tion by E. coli phages (Stanek and Falkinham 2001; Guzmán
Luna et al. 2009). Enzyme release is detected by the generation
of a bioluminescence or colour signal after cleavage of a spe-
cific substrate. These assays are highly sensitive, generating a
detectable signal in a short time (≈3 h) even when starting with
a low phage amount. Such methods are compatible with high-
throughput and, in theory, work with any phage but may need to
be optimized (e.g. enzyme/substrate selected) for each bacterial
species.
The aptitude of surface plasmon resonance (SPR) techniques
to measure and quantify molecules bound to surfaces was
explored to study the interaction between phages and bacte-
rial host (Garcı́a-Aljaro et al. 2008). For this method, bacteria are
immobilized on gold sensor chips using avidin-biotin, and bind-
ing of phages to the bacteria and consequent bacterial lysis can
be detected and measured with high sensitivity in just 2 h. As it
is, however, the method is not compatible with high-throughput
screening as only a strain-phage pair can be tested simultane-
ously. A microfluidics adaptation of the method, in which multi-
ple channels are created to test multiple phages simultaneously,
could provide an interesting solution.
Cell respiration can also be used as a reporter for cellular
growth and, consequently, for phage infection. Using this prin-
ciple, Henry and colleagues developed the OmniLogTM system,
in which cell respiration is measured using redox chemistry via
reduction of a tetrazolium dye that produces a colour change
measured in microtiter plates (Henry et al. 2012). Successful
phage infection is detected by a reduction in colour due to
reduced bacterial growth and respiration. Such method is simple
and high-throughput, but might be limited to aerobic bacteria.
A simple approach was also recently suggested based on the
analysis of optical density kinetics in bacterial cultures for the
detection and quantification of phages (Rajnovic, Muñoz-Berbel
and Mas 2019). This method detects phages at low amounts with
a response time of 3.5 h, and is susceptible of miniaturization
and automation for high-throughput applications that can be
implemented in routine analysis. A possible drawback is that it
relies solely on a change in optical density of the bacterial cul-
ture, which is not always observable for lytic phages.
In the future, a simple and fast high-throughput method for
phage screening should be established and implemented in clin-
ical settings and in phage banks, if phage therapy is to be widely
used as a treatment option.
Efficacy of phages against biofilms
In nature and in the human body, bacteria are most often found
in the form of a biofilm. A biofilm can be defined as a popu-
lation of bacteria attached to a surface and embedded within
a self-produced matrix (Hobley et al. 2015). In biofilms, bacte-
rial cells closely collaborate as a strategy for survival and per-
sistence in harsh environments (Costerton et al. 1995), e.g. pro-
viding increased tolerance to antibiotics (Costerton, Stewart and
Greenberg 1999; Stewart and Costerton 2001). Phage-bacteria
interactions have been mostly studied in planktonic cultures,
but these interactions have been shown quite distinct for bac-
teria in a biofilm form. Studies have revealed the therapeutic
potential of phages to control both mono-species (Curtin and
Donlan 2006; Fu et al. 2010; Alves et al. 2015; Melo et al. 2016) and
dual-species biofilms (Sillankorva, Neubauer and Azeredo 2010;
Lehman and Donlan 2015; Gutiérrez et al. 2015b), but multiple
works have also unveiled the impressive complexity and diver-
sity of phage-biofilm interactions.
Within biofilms, bacteria are protected by a matrix composed
mainly of polysaccharides, lipids, extracellular DNA, and pro-
teins (Hobley et al. 2015; Seviour et al. 2019). The matrix is a
major factor influencing the ability of a phage to successfully
disturb a biofilm (Darch et al. 2017), via several suggested mech-
anisms. The matrix can adsorb phages (Bull et al. 2018) or sim-
ply form a physical barrier for phage diffusion (González et al.
2018; Dunsing et al. 2019), preventing phages from reaching and
infecting the living cells within the biofilm (Fig. 1D). Phages have,
however, developed strategies to counteract the limiting effects
of the matrix on their activity (Pires et al. 2017a). Many phages
encode polysaccharide-degrading enzymes known as depoly-
merases, which are used to degrade capsular polysaccharides
of bacteria and thereby give the phage access to its receptor on
the bacterial cell surface. Some depolymerases can also degrade
exopolysaccharides of the biofilm matrix and improve access of
the phages to the bacterial cells (Harper et al. 2014; Gutiérrez et al.
2015a). The activity of depolymerases tends to be very specific
for a certain polysaccharide type, and the use of a phage cock-
tail encoding for different depolymerases may represent a good
treatment solution, and even enhance the activity of other non-
depolymerase producing phages (Schmerer, Molineux and Bull
2014).
The spatial organization of the biofilm is also a determinant
factor for phage infection. To form a biofilm, cells organize so
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that localized niches are created with distinct nutrient availabil-
ity and consequently with bacteria of distinct motility, metabolic
state, and gene expression, all of which affect the capacity of
phages to infect biofilm cells. The diffusion of the phage through
the biofilm is limited by the close proximity of the cells, which
may cause multiple phages to infect the same host cell and
decrease the number of progeny phages the cell generates (Tay-
lor, Penington and Weitz 2017). Still, it is also possible that local
infection of a biofilm leads to a significant disruption of the
biofilm structure, ultimately leading to its dispersal and easier
removal.
The establishment of nutrient gradients often leads to the
generation of dormant persister cells in the deeper layers of the
biofilm, where nutrient resources are scarce. Phages infecting
these metabolically inactive cells are expected to be unable to
propagate as they, in principle, cannot use the (inactive) replica-
tion machinery of the cell (Loś et al. 2007; Pearl et al. 2008). How-
ever, a Staphylococcus infecting phage was recently shown capa-
ble of propagating in dormant staphylococcal cells, a feature
expected to be present in other phages yet to discover (Melo et al.
2018; Tkhilaishvili et al. 2018). Additionally, phages can remain
within the persister cells until they exit the state of dormancy,
being then able to propagate as normal (Pearl et al. 2008).
Gene expression in biofilms is frequently controlled by quo-
rum sensing, which involves the use of extracellular signal
molecules that sense population density to coordinate gene
expression (Ng and Bassler 2009). Quorum sensing can be used
by bacteria to respond to phage infections, for example by reg-
ulating expression of CRISPR-Cas systems (Patterson et al. 2016;
Høyland-Kroghsbo et al. 2017) and of phage receptors (Høyland-
Kroghsbo, Maerkedahl and Svenningsen 2013; Tan, Svenningsen
and Middelboe 2015), and also by regulating the production of
biofilm matrix (Parsek and Greenberg 2005). Some phages have
developed strategies to exploit the bacterial quorum sensing
system to guide their lysis-lysogeny decision either by encod-
ing receptors for the bacterial quorum sensing molecules (Silpe
and Bassler 2019) or by expressing their own extracellular sig-
nalling molecules once inside the bacteria (Erez et al. 2017). By
sensing the bacterial population, phages can sense a favourable
or unfavourable environment for lytic development.
Biofilms are also known to release outer membrane vesicles
(OMVs) in high number. These OMVs may contain outer mem-
brane proteins used as receptors by some phages, and there-
fore work as a decoy for phage infection, protecting biofilm cells
from phages (Manning and Kuehn 2011; Reyes-Robles et al. 2018).
Nevertheless, phages that use receptors other than outer mem-
brane proteins (e.g. lipopolysaccharides) are not affected by such
strategy.
Dispersion of bacteria from a biofilm for colonization of a new
niche is an important step of the biofilm life cycle. Phages may
be interesting solutions to control the spreading step of a biofilm
infection, as some phages unable to eradicate a biofilm can still
inhibit dispersal of migrating bacteria and the establishment of
new colonies (Darch et al. 2017).
Most in vitro work in biofilms has been performed using sin-
gle strains. Natural biofilms, however, are often multi-strain
or multi-species, which significantly affects the biofilm spatial
organization and the interaction with phages. The specific out-
come of phage infection in a multi-species biofilm seems to
strongly depend on the bacterial species composing the biofilm
(e.g. whether they establish synergist or antagonist interac-
tions). Some studies have reported the ability of phages to target
the susceptible host in the biofilm independently of the pres-
ence of a non-susceptible strain (Harcombe and Bull 2005; Kay
et al. 2011; Gutiérrez et al. 2015a). A few works, however, suggest
the presence of insensitive strains to provide spatial structure-
associated protection to the sensitive bacteria against phage
infection, thereby reducing the efficacy of phage treatment (Tait,
Skillman and Sutherland 2002; Testa et al. 2019). Broad host
range phages (Kim et al. 2012) as well as phages carrying depoly-
merases (Pei and Lamas-Samanamud 2014) may be particularly
efficient against multispecies biofilms. In the latter case, the
diversity and heterogeneous distribution of exopolysaccharides
on a multi-species biofilm may limit depolymerase activity.
The complexity of phage-biofilm interactions is increased by
evidence of promoted biofilm formation induced by exposure
to certain phages (Lacqua et al. 2006; Tan, Dahl and Middelboe
2015; Henriksen et al. 2019). Two scenarios have been proposed
for this phenomenon. In the first scenario, changes in biofilm
are thought to occur as a consequence of the specific bacte-
rial receptor used by the phage. Mutations in these receptors
occur as a response to infection and may lead to changes in the
biofilm cells that result in increased biofilm formation (Scanlan
and Buckling 2012; Fernández et al. 2017; Henriksen et al. 2019).
The second scenario suggests that some phages may benefit
from increased biofilm formation, with entrapment of phages
in the biofilm matrix providing protection against harsh envi-
ronmental factors (Agún et al. 2018; Gabiatti et al. 2018). In this
scenario, an increase of the biofilm is beneficial for both bacteria
and phage.
Overall, the potential of phages to control biofilm infections
is clear. However, the complexity and diversity of phage-biofilm
interactions limit broad conclusions and call for more research
before phage therapy becomes a real solution for biofilm-related
infections.
Evolution of bacterial resistance to phages
One of the major concerns in phage therapy is the possible emer-
gence of bacteriophage-insensitive mutants (BIMs) that could
hamper the success of this therapy (Fig. 1E). Over the last years,
several studies have addressed the problem of bacterial resis-
tance to phages, demonstrating that the emergence of phage-
resistant mutants is frequent and almost unavoidable (Oechslin
2018; McCallin and Oechslin 2019). The resistance mechanisms
used by bacteria to counter-attack phage evasion include, among
others: (i) prevention of phage adsorption by loss or modifica-
tion of bacterial receptors; (ii) prevention of phage DNA entry
by superinfection exclusion systems; (iii) degradation of phage
DNA by restriction-modification (R-M) systems and other related
systems (BREX, DISARM, etc) or by CRISPR-Cas systems; (iv) use
of abortive infection systems that block phage replication, tran-
scription or translation; or (v) cyclic oligonucleotide-based anti-
phage signalling systems (Labrie, Samson and Moineau 2010;
Bernheim and Sorek 2020).
A number of in vitro studies have reported the emergence of
BIMs within a short period of time after phage treatment (Fu et al.
2010; Le et al. 2014; Oechslin et al. 2016; Pires et al. 2017b). In most
of these studies, bacterial resistance to phages was caused by
mutations on genes encoding phage receptors, which include
lipopolysaccharides, outer membrane proteins, capsules, flag-
ella, pili, among others. The emergence of phage-resistant vari-
ants has also been noticed in vivo in several animal models as
well as in human pilot studies and case reports (Oechslin 2018;
McCallin and Oechslin 2019). However, some studies have high-
lighted the fact that the evolution of resistance observed in vitro
does not resemble what actually happens in vivo. For example,
Oechslin et al. studied the efficacy of a phage cocktail in the
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treatment of P. aeruginosa endocarditis and observed that BIMs
emerged in vitro but not in vivo (Oechslin et al. 2016). According to
the authors, this occurred probably because the bacterial muta-
tions on phage receptors rendering them resistant might incur
fitness costs, with the bacteria becoming less virulent and there-
fore easier to eliminate by the immune system. Other authors
have also reported the attenuated virulence of BIMs in conse-
quence of modifications in cell surface receptors for other bac-
terial species (Filippov et al. 2011; León and Bastı́as 2015; Sumrall
et al. 2019).
Bacterial resistance to phages can be circumvented using dif-
ferent approaches (McCallin and Oechslin 2019). The most com-
mon is the combination of multiple phages, preferentially tar-
geting different receptors and with complementary host ranges,
in a single preparation, which is usually known as a phage cock-
tail. In addition to displaying a larger coverage against a partic-
ular bacterial species, such cocktails can also arrest the emer-
gence of BIMs. These are the main reasons behind the preferred
use of phage cocktails over single phage preparations in therapy.
Phage cocktails might have a fixed composition covering a broad
host range (prêt-à-porter) or a customized formulation designed
for a particular patient (sur-mesure) (Pirnay et al. 2011). Another
strategy commonly used to deal with the problem of resistance
during phage treatment is the replacement of the phage against
which the bacteria developed resistance by a phage that is active
against the resistant variant. While this is not easy for antibi-
otics, when it comes to phages it can be quite simple given
their abundance and diversity in nature as a result of their con-
stant co-evolution with bacteria (Rohde, Wittmann and Kutter
2018). Lastly, the combination of phages with antibiotics or other
antimicrobial agents can also be used to avoid the development
of bacterial resistance and to improve the therapeutic efficacy
(see below for more detail) (Torres-Barceló and Hochberg 2016;
Tagliaferri, Jansen and Horz 2019).
Regulatory framework of phage therapy
Regulatory authorities have classified phages as biological sub-
stances and, as such, phages fall within the scope of the phar-
maceutical legislation (Pelfrene et al. 2016; Reindel and Fiore
2017). The regulatory framework in the European Union and in
the United States stipulates that a marketing authorization is
required for medicinal products prepared industrially or manu-
factured by a method involving an industrial process (Fig. 1F).
As such, marketing a phage product requires proof of both
safety and efficacy, and also of quality by manufacture under
GMP (Directive 2001/20/EC 2001; Pelfrene, Sebris and Cavaleri
2019). GMP compliance requires extensive financial resources
(Pelfrene et al. 2016; Jault et al. 2019) and is therefore a critical
obstacle for hospitals or non-for-profit phage therapy centres.
Current legislation calls also for predetermined qualitative and
quantitative evaluation of every constituent of the medicinal
product. For phages, recommended criteria (Parracho, Burrowes
and Enright 2012; Pelfrene et al. 2016) include the absence of
prophages and antibiotic resistance in the bacteria used to pro-
duce the phage(s), the lytic (non-temperate) and specific activ-
ity of individual phages on the target bacteria, the control for
impurities (e.g. endotoxins, residual reagents) in phage prepa-
rations, and the test for potency and purity of the phages. This
strict regulation is somehow suitable for phage cocktails of fixed
composition (prêt-à-porter) manufactured at industrial scale, but
is certainly inadequate for patient-specific, customized, phage
cocktails (sur-mesure) whose composition is variable and not
intended for large-scale distribution (Directive 2001/83/EC 2001;
Pelfrene, Sebris and Cavaleri 2019) (Pirnay et al. 2011).
Discussions between phage sponsors and regulatory agen-
cies are ongoing to set more satisfactory regulations for per-
sonalized phage therapy. The European Union currently allows
for a few exceptions on the requirement to obtain a product
license, which apply to the magistral formula (any medicinal
product prepared in a pharmacy in accordance with a prescrip-
tion for an individual patient (Nahler 2009a)) and the officinal
formula (any medicinal product which is prepared in a phar-
macy in accordance with the prescriptions of a pharmacopoeia
and is intended to be supplied directly to the patients served
by the same pharmacy (Nahler 2009b)), and for any advanced
therapy medicinal product (ATMP, medicinal product which is
either a gene therapy medicinal product, a somatic cell ther-
apy medicinal product, or a tissue engineered product), if pre-
pared on a ‘non-routine basis according to specific quality stan-
dards, and used within the same Member State in a hospi-
tal under the exclusive professional responsibility of a medi-
cal practitioner, in order to comply with an individual medi-
cal prescription for a custom-made product for an individual
patient’ (Directive 2001/83/EC 2001; Pelfrene, Sebris and Cava-
leri 2019). An exemption is applied also for compassionate use,
a treatment option that allows an unauthorized (in develop-
ment) medicine to be made available to groups of patients who
have a disease with no satisfactory authorized therapies and
who cannot enter clinical trials. However, compassionate use
is only allowed for medicines undergoing clinical trials or that
have entered the marketing authorization application process
(Compassionate use | European Medicines Agency 2004; Pel-
frene, Sebris and Cavaleri 2019).
Due to the current unsatisfactory regulatory framework,
Member States of the European Union are finding national solu-
tions for phage therapy regulation. The Belgian authorities are
pioneering phage therapy regulations in Western countries by
establishing a national regulation of magistral preparation of
tailor-made phage medicines (Pirnay et al. 2018). The regulation
requires issuing of a monograph that judges in written form
the quality of the phage active pharmaceutical ingredient (API)
to be used for the preparation of the medicinal product. Every
stock of the phage therapy medicinal product is then tested by
a Belgian approved laboratory to confirm the phage(s) comply
with the phage API monograph(s), issuing a certificate of anal-
ysis that approves its use. A pharmacist then uses the certified
phage stock for preparing a customized medicinal product based
on the prescription of a physician (Pirnay et al. 2018). This pro-
cess has already allowed the implementation of phage therapy
in Belgium, but it is not yet ideal as all responsibility is given
to the prescriber and the pharmacist (Fauconnier 2017). Similar
regulatory principles were already in practice, for example, in
Georgia and Russia. In Georgia, ready-to-use phage medicines
require a marketing authorization according to regular regula-
tion, while customized phage preparations may be prepared as
magistral preparation in an authorized pharmacy (Parfitt 2005).
The Russian pharmacopeia includes a monograph on phages
for prophylactic and therapeutic use (Russian Pharmacopoeia
OFS.1.7.1.0002.15 2020).
Other countries are also finding similar solutions. France
has issued recommendations for the use of phage medicinal
products under the nominative Temporary Authorization for
Use (ATUn) (Phagothérapie 2016). An ATUn can be issued by
hospital pharmacies, for a single patient who cannot participate
in a clinical trial, at the request and under the responsibility of
the prescribing physician, allowing for the use of a medicinal
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product without market approval if its efficacy and safety
balance is presumed favourable for the patient, in the absence
of any approved treatment. In the United States, phages can be
and have been used following the Food and Drug Administra-
tion (FDA) emergency investigational new drug (eIND) pathway
(Schooley et al. 2017; LaVergne et al. 2018).
Further clinical evidence of the success of phage therapy in
human trials conducted to modern standards would help fos-
ter regulatory advance (Pelfrene et al. 2016), but current regu-
latory issues affect also the conduct of clinical trials. A new
provision in the regulatory framework of the European Union
may facilitate clinical trials with phage medicinal products, by
exempting GMP requirements in the preparation of investiga-
tional medicine products (IMPs), ‘where this process is carried
out in hospitals, health centers or clinics legally authorized in
the Member State concerned to carry out such process and if the
IMPs are intended to be used exclusively in hospitals, health cen-
ters or clinics taking part in the same clinical trial in the same
Member State’ (Regulation (EU) No 536/2014 2014).
In summary, current regulations will certainly undergo seri-
ous modifications before a fully practicable regulation is imple-
mented for phage therapy, as well as other customized medici-
nal products meant to be tailored to an individual patient.
THE FUTURE OF PHAGE THERAPY
Phages in One Health approach
It is estimated that at least 6 out of 10 known infectious dis-
eases in humans are originated in animals (Zoonotic Diseases
| One Health | CDC 2017). Moreover, the selective pressure on
phytobacteria drives evolution in a vast number of defence
mechanisms, which can result in increased virulence towards
humans, especially those with advanced age, immunodeficiency
or cancer (Erken, Lutz and McDougald 2013; Falkinham, Pru-
den and Edwards 2015). The One Health concept recognizes
that the health of humans and animals as well as our envi-
ronment are all intertwined. To improve the lives of all liv-
ing species, the One Health program proposes the integration
of human medicine, veterinary medicine and environmental
science (http://www.onehealthinitiative.com/). Agriculture and
food safety are also included in this holistic and multi-sectoral
approach to tackle antimicrobial resistance (Baum et al. 2017;
Hernando-Amado et al. 2019). Although microorganisms will
inevitably develop resistance towards antibiotics as a conse-
quence of genetic mutations or horizontal gene transfer, the
problem of resistance is worsened by the misuse of antibiotics
since their discovery. A clear example is the use of antibiotics
as growth promoters at livestock farms, which impelled the
European Union to create stricter regulations to control their
widespread usage (Kittler et al. 2017). To mitigate the spread of
antimicrobial resistance, new alternative therapeutics under the
One Health view are needed. Since their discovery, phages are
being applied for the control of bacterial proliferation in sev-
eral microbiomes, such as humans (as reviewed above), animals
(Oliveira, Sereno and Azeredo 2010), several environmental set-
tings (e.g. wastewater treatments) (Withey et al. 2005), and on
food industry (Abuladze et al. 2008). A good example of the global
use of phages are the diverse application opportunities in food
industry, where they can be used at all stages of food processing,
from slathering and crops to food transportation (reviewed by
(Goodridge and Bisha 2011)), even improving the shelf life of food
products (Alves et al. 2019). In fact, several phage-based products
to be applied in food-stuff have already received the GRAS (gen-
erally recognized as safe) classification by the FDA in the United
States (Sarhan and Azzazy 2015). Therefore, the use of phages is
consistent with the One Health approach as they can be applied
in different settings (e.g. food, animals or crops) thus prevent-
ing the overuse of antibiotics and the dissemination of antibiotic
resistance to humans (Kittler et al. 2017).
Emerging approaches
The use of phages for the control of bacterial infections might be
improved via combination with other agents, especially when
targeting the complex biofilm communities (Koo et al. 2017).
These combined therapies have often the advantage of lim-
ited development of resistance towards agents with distinct
modes of action due to the fitness cost associated with resis-
tance against multiple factors (Torres-Barceló and Hochberg
2016; Chaudhry et al. 2017).
Probably the most obvious combination is that of phages
and antibiotics (Fig. 1G). When used simultaneously, phages
and antibiotics have shown synergistic effects and effective-
ness against planktonic cells (Bedi, Verma and Chhibber 2009;
Nouraldin et al. 2016; Jansen et al. 2018; Yazdi, Bouzari and
Ghaemi 2018) and (especially old) biofilms (Bedi, Verma and
Chhibber 2009; Rahman et al. 2011; Chaudhry et al. 2017; Akturk
et al. 2019), where the individual treatments had restricted suc-
cess. In cases where repeated treatment with phages increased
biofilm production, the combined use of phage and antibiotics
resulted in biofilm eradication (Henriksen et al. 2019). Structural
changes in the biofilm caused by one or both agents may be
behind the enhanced efficacy. For example, removal of periph-
eral cells by the phage may lead to increased resource availabil-
ity for inner cells and improve their metabolic state, making the
cells more susceptible towards phages and certain antibiotics
(Chaudhry et al. 2017). Antibiotics may also themselves cause
changes in the biofilm architecture and thereby enable increased
invasion of biofilms by phages (Dı́az-Pascual et al. 2019).
Synergism between antibiotics and phages does not hap-
pen for all phage-antibiotic combinations (Knezevic et al. 2013;
Kamal and Dennis 2015; Jansen et al. 2018) and high doses of
antibiotics can also antagonize phage propagation (Dickey and
Perrot 2019). This is particularly evident when using antibiotics
that target cell protein synthesis (Akturk et al. 2019). But in some
cases, even though no synergism in antimicrobial activity is
observed, the combined use of phages and antibiotics signifi-
cantly reduces or even prevents the development of antibiotic-
and phage-resistant bacteria (Coulter et al. 2014; Dickey and Per-
rot 2019).
While several studies have looked into the effect of phage-
antibiotic therapies, few have developed a rational approach to
explore the bacterial response to these agents. An example of
such strategy is the isolation of phages targeting specific outer
membrane proteins that are used by bacteria as multidrug efflux
pumps. Development of resistance to this phage would require
the bacteria to change the efflux pump and therefore increase
sensitivity against certain antibiotic classes (Chan et al. 2016).
This approach was successfully employed to save a patient suf-
fering from a chronic prosthetic vascular graft infection caused
by P. aeruginosa, in which phage OMKO1 binding to efflux pump
proteins was used in combination with ceftazidime; evolution of
phage resistance led to increased antibiotic sensitivity and the
infection was resolved (Chan et al. 2018). Approaches like this
are not only efficient but also extend the lifetime of our current
antibiotics.
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Phages can also be co-administered with enzymes for
improved activity. For example, depolymerases can be used
together with phages that do not naturally express them to
improve their activity against biofilms (Gutiérrez et al. 2015a).
DNAse enzymes can also be used together with phages to
degrade the DNA component of the biofilm matrix and improve
phage activity (Hughes et al. 2006). Other successful cases com-
bined phages with chlorine (Zhang and Hu 2013), triclosan,
chlorhexidine, hydrogen peroxide (Agún et al. 2018), cobalt (II)
sulphate (Chhibber, Nag and Bansal 2013), xylitol (Chhibber,
Bansal and Kaur 2015), honey (Oliveira et al. 2017) and probiotics
(Woo and Ahn 2014).
The modification of phage genomes is also being explored
to improve phage therapy outcomes (Fig. 1H). This approach
is being fuelled by recent advances in the synthetic biology
field, with many techniques now available to engineer phage
genomes (Martel and Moineau 2014; Ando et al. 2015; Pires et al.
2016; Kilcher et al. 2018). The host range of a phage is one of
the main targets to engineer. While the high host specificity
of phages is advantageous by preventing targeting of benefi-
cial bacteria, it also implies that it is almost impossible to tar-
get all strains within a given species using a single phage. Tai-
lored control of a phage’s host range is therefore a major goal
in phage therapy. Working towards this goal, several studies
have swapped receptor-binding protein genes between phages
of different families, successfully exchanging the host range of
the phage. This has been possible between phages infecting the
same (Yoichi et al. 2005; Mahichi et al. 2009) or different species
(Ando et al. 2015). Others had fused a heterologous receptor bind-
ing domain to the receptor binding protein of a phage, thereby
increasing the phage host range (Marzari et al. 1997; Heilpern
and Waldor 2003).
Phages can also be engineered to deliver specific cargo to
enhance the phage antimicrobial activity. For example, enzymes
such as dispersin B and lactonase have been engineered into
phage T7 to increase the phage activity against biofilms (Lu
and Collins 2007; Pei and Lamas-Samanamud 2014). Dispersin
B, a glycoside hydrolase, is expressed at high levels during T7
infection and released upon cell lysis into the biofilm environ-
ment, where it degrades the matrix; by doing so, dispersin B
increases the phage efficacy on removing both bacteria and
matrix from the biofilm (Lu and Collins 2007). Lactonase was
also engineered into phage T7, but to interfere with the bac-
terial quorum sensing, making use of its ability to inactivate
the quorum sensing acylated homoserine lactones (Pei and
Lamas-Samanamud 2014). Inactivation of the quorum sens-
ing molecules interferes with biofilm formation and leads to
improved biofilm control by the engineered phage. Curiously,
this strategy was shown to work in multi-species biofilms, where
quorum sensing molecules of one species also increase biofilm
formation of the second species, and inhibition of the molecules
by the lactonase reduces biofilm formation in both species. This
may therefore be an interesting alternative treatment against
multi-species biofilms in the future.
While most engineering efforts have centred on lytic phages,
temperate phages have also been the subject of a few engineer-
ing experiments for phage therapy purposes. The most obvious
approach consists on genetically modifying phages to become
exclusively lytic. This has been accomplished by deletion of the
genomic module responsible for the establishment of lysogeny
(Dorscht et al. 2009; Zhang et al. 2013; Kilcher et al. 2018). The
creation of virulent mutants of otherwise temperate phages
can easily extend the number and diversity of phages available
for therapeutic purposes. A great example of the value of this
approach is the recent use of a cocktail composed of one nat-
ural lytic phage and two engineered temperate phages to suc-
cessfully treat a 15-year-old patient with cystic fibrosis with a
disseminated Mycobacterium abscessus infection (Dedrick et al.
2019). The temperate phages were engineered to become lytic
via removal of the repressor of the lytic cycle, and the cocktail
was administered intravenously and was well tolerated. Geneti-
cally engineered phages are not readily accepted for phage ther-
apy due to the inherent ethical issues of genetically modified
organisms (GMOs) but this case study clearly shows that engi-
neering approaches are useful. The possibility of using tem-
perate phages engineered into lytic forms in phage therapy
increases the number of phages available for therapeutic use, by
reducing/removing the risk of transduction of bacterial genetic
information (e.g. virulence-related genes) mediated by temper-
ate phages (Monteiro et al. 2019).
Temperate phages have also been engineered to deliver syn-
thetic gene networks, exploiting their natural capacity to inte-
grate into the host bacterium chromosome, where the phage
expresses the molecule of interest. Phages have been modi-
fied as adjuvants to antibiotics, by codifying dominant antibiotic
sensitive genes (Edgar et al. 2012) or CRISPR-Cas systems (Bikard
et al. 2014; Yosef et al. 2015) that revert antibiotic resistance in
bacteria, or by codifying CRISPR-Cas systems designed to target
bacterial cells (Park et al. 2017).
Overall, engineering approaches can potentially improve
the antimicrobial properties of phages and create innovative
strategies for fighting bacterial infections. The consequences
of genetic manipulation of phage genomes must be carefully
addressed, but phage engineering strategies should be effec-
tively considered as a therapeutic option. Additionally, engi-
neered phages have easier patentability than natural phages
and may therefore have more commercial interest.
Can phage resistance become a global problem?
Phage therapy frequently raises the question of whether the
global use of phages could lead to a widespread problem sim-
ilar to antibiotic resistance. A definitive answer does not exist.
First, phages will unlikely be used as a first line treatment
against bacterial infections as it happens with antibiotics. In
a future perspective, phage therapy is expected to be applied
only in clinical cases of patients who experienced the fail-
ure of antibiotic treatments. Additionally, contrary to antibi-
otic therapy, phage preparations for therapeutic applications are
expected to be developed in a personalized way by formulat-
ing phage cocktails that might delay the emergence of bacterial
resistance to phages.
In the scenario of phages being extensively used in the future
both as therapeutic and as environmental bio-control agents, it
is possible that a strong selective pressure is imposed towards
the development of resistant bacteria. Still, it seems improbable
that no phage will be available in nature to infect a bacteria that
has become resistant to a previous phage. In fact, the long and
continuous co-evolution of phages and bacteria (Dion, Oechslin
and Moineau 2020) have resulted in bacteria evolving a range
of mechanisms to avoid phage predation, and in phages devel-
oping effective counter-strategies to evade the antiviral systems
(Samson et al. 2013). This arms race between phages and their
bacterial hosts will not come to an end and, despite the emer-
gence of resistant bacteria, phages will certainly find a way to
ensure their propagation. The use of strategies as combined
therapies and genome engineering may be an additional aid to
prevent the spread of phage resistance. Still, further studies are
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required to guarantee that the global use of phages will not even-
tually compromise its efficacy.
FINAL REMARKS
In an era of global crisis for antibiotics, phage therapy has
emerged as a potential alternative with already proven cases of
clinical success. The generic use of phages for biocontrol meets
the One Health Approach and is well aligned with the recently
established European Green Deal (European Commission 2019)
that recommends reducing significantly the use of antibiotics
in food production. On the other hand, scientific advances have
contributed to a better knowledge of phage-bacteria interac-
tion enabling a safer and more efficient phage therapy. So, the
conditions needed for the reintroduction of phage therapy as a
therapeutic practice are met. Nevertheless, the widespread use
of phage therapy creates additional challenges that go beyond
the clinic standpoint and carries extra demands. These include
(i) the need of increasing phage collections of reference phage
banks; (ii) the development of efficient phage screening meth-
ods for the fast identification of the therapeutic phage; (iii) the
establishment of efficient phage therapy strategies that tackle
infectious biofilms; (iv) the set-up of phage production protocols
that assure quality and safety of phage preparations and (v) the
guarantee of stability of phage preparation during storage and
transport.
As infectious diseases have no borders, a global action plan
to make phage therapy worldwide available is needed. This
obviously requires an active collaboration between countries
for overcoming logistic and regulatory challenges, and between
clinicians and scientists for filling current knowledge gap and
fostering advances in the field.
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Garcı́a-Aljaro C, Muñoz-Berbel X, Jenkins ATA et al. Sur-
face plasmon resonance assay for real-time monitoring of
somatic coliphages in wastewaters. Appl Environ Microbiol
2008;74:4054–8.
Garcı́a R, Latz S, Romero J et al. Bacteriophage Production Models:
An Overview. Front Microbiol 2019;10:1187.
Gonzalez-Menendez E, Fernandez L, Gutierrez D et al. Compar-
ative analysis of different preservation techniques for the
storage of Staphylococcus phages aimed for the industrial
development of phage-based antimicrobial products. PLoS
One 2018;13:e0205728.
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Rajnovic D, Muñoz-Berbel X, Mas J. Fast phage detection and
quantification: An optical density-based approach. PLoS One
2019;14:e0216292.
Regulation (EU) No 536 /2014. Regulation (EU) No 536/2014 of
the European Parliament and of the Council of 16 April 2014
on clinical trials on medicinal products for human use, and
repealing Directive 2001/20/EC (2014) Official Journal L158, p.
1–76. 2014.
Regulski K, Champion-Arnaud P, Gabard J. Bacteriophage manu-
facturing: from early twentieth-century processes to current
GMP. Bacteriophages, Switzerland AG: Springer International
Publishing, 2018, 1–31.
Reindel R, Fiore CR. Phage therapy: considerations and chal-
lenges for development. Clin Infect Dis 2017;64:1589–90.
Reyes-Robles T, Dillard RS, Cairns LS et al. Vibrio cholerae outer
membrane vesicles inhibit bacteriophage infection. J Bacteriol
2018;200:e00792–17.
Rhoads DD, Wolcott RD, Kuskowski MA et al. Bacteriophage ther-
apy of venous leg ulcers in humans: results of a phase I safety
trial. J Wound Care 2009;18:237–8, 240–3.
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